Biogen struck a deal that could bring a digital therapeutic to its multiple sclerosis product portfolio. The drugmaker is partnering with startup MedRhythms in the development of a therapy that combines sensors, software, and music to improve walking problems in multiple sclerosis patients.
MedRhythms, a digital health startup using sensors and music for post-stroke walking rehabilitation, received an FDA Breakthrough Device Designation.
The future looks bright for the integrated specialty pharmacy model – for health systems, providers, and most importantly, for patients.
The company, Portland, Maine-based MedRhythms, is using sensors, software and music to build evidence-based neurologic interventions to help stroke patients improve their walking.